PremiumThe FlyZealand Pharma completes enrollment in ZUPREME-1 trial Zealand Pharma upgraded to Buy from Hold at SEB Equities Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact PremiumThe FlyZealand Pharma price target lowered to DKK 1,050 from DKK 1,080 at Berenberg Zealand Pharma’s Earnings Call: Clinical Gains and Challenges Zealand Pharma price target lowered to DKK 750 from DKK 755 at Morgan Stanley PremiumThe FlyZealand Pharma price target lowered to DKK 750 from DKK 815 at Deutsche Bank Ironwood jumps after FDA rejects Zealand short bowel syndrome drug application Zealand Pharma says FDA issues CRL for glepaglutide NDA 
